A novel therapeutic system for malignant glioma: Nanoformulation, pharmacokinetic, and anticancer properties of cell-nano-drug delivery

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 2, 2013, Pages 222-232

  Tao, Youhua ^a   Ning, Miaomiao ^a   Dou, Huanyu ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Bone marrow derived monocytes macrophages; Glioma; Polymeric nanoparticles

Indexed keywords

ACTIN FILAMENT; ANTI-TUMOR ACTIVITIES; ANTICANCER PROPERTIES; CELL UPTAKE; CELL VIABILITY; CHEMOSENSITIVITY; CO-CULTURES; CYTOARCHITECTURE; CYTOSKELETONS; DELIVERY SYSTEMS; EFFICIENT SYSTEMS; GLIOMA; MALIGNANT GLIOMA; MICROTUBULES; MONOCYTES/MACROPHAGES; NANOFORMULATION; PACLITAXEL; POLYMERIC NANOPARTICLES; THERAPEUTIC EFFICACY; THERAPEUTIC SYSTEMS; TOXICOLOGICAL PROPERTIES;

BONE; CYTOLOGY; DRUG DELIVERY; MACROPHAGES; PROTEINS; TOXICITY; TUMORS;

POLYMERS;

NANOCARRIER; PACLITAXEL; POLYGLACTIN;

ACTIN FILAMENT; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CHEMOSENSITIVITY; COCULTURE; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOSKELETON; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG RELEASE; DRUG UPTAKE; GLIOBLASTOMA; MACROPHAGE; MALE; MICELLE; MICROTUBULE; MOUSE; NONHUMAN; POLYMERIZATION; TOXICITY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; MACROPHAGES; NANOSTRUCTURES; PACLITAXEL;

EID: 84873737627     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.10.006     Document Type: Article

References (34)

1. Burton E.C., Lamborn K.R., Feuerstein B.G., Prados M., Scott J., Forsyth P., et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002, 62:6205-6210.
2. Lin C.L., Lieu A.S., Lee K.S., Yang Y.H.C., Kuo T.H., Hung M.H., et al. The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol 2003, 60:402-406. [discussion 406].
3. Ulrich T.A., de Juan Pardo E.M., Kumar S. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 2009, 69:4167-4174.
4. Kadiu I., Glanzer J.G., Kipnis J., Gendelman H.E., Thomas M.P. Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotox Res 2005, 8:25-50.
5. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 2006, 113:477-485.
6. Reijerkerk A., Kooij G., Van der Pol S.M.A., Leyen T., Van het Hof B., Couraud P.O., et al. Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier. J Immunol 2008, 181:3567-3574.
7. Baek Y.W., An YJ. Microbial toxicity of metal oxide nanoparticles (CuO, NiO, ZnO, and Sb2O3) to Escherichia coli, Bacillus subtilis, and Streptococcus aureus. Sci Total Environ 2011, 409:1603-1608.
8. Kumar Naraharisetti P., Yung Sheng Ong B., Wei Xie J., Kam Yiu Lee T., Wang C.H., Sahinidis N.V. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma. Biomaterials 2007, 28:886-894.
9. Gupta H., Aqil M., Khar R.K., Ali A., Bhatnagar A., Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2009, 6:324-333.
10. Wei Z., Hao J.G., Yuan S., Li Y.J., Juan W., Sha X.Y., et al. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int J Pharm 2009, 376:176-185.
11. Muthu M.S., Rawat M.K., Mishra A., Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine 2009, 5:323-333.
12. Lu H.F., Lim W.S., Wang, J., Tang Z.Q., Zhang P.C., Leong K.W., et al. Galactosylated PVDF membrane promotes hepatocyte attachment and functional maintenance. Biomaterials 2003, 24:4893-4903.
13. Wiesner S.M., Freese A., Ohlfest J.R. Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies. Neurosurg Focus 2005, 19:E3.
14. Barbosa P.R., Valvassori S.S., Bordignon C.L., Kappel V.D., Martins M.R., Gavioli E.C., et al. Association of EGFR c. 2073A>T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case-control study. Int J Biol Markers 2008, 23:140-146.
15. Amin M.R. A topographic analysis of the proliferating tumor cells in an autopsied brain with infiltrative thalamic glioma. Brain Tumor Pathol 2002, 19:5-10.
16. Yoshikawa K., Kajiwara K., Morioka J., Fujii M., Tanaka N., Fujisawa H., et al. Improvement of functional outcome after radical surgery in glioblastoma patients: the efficacy of a navigation-guided fence-post procedure and neurophysiological monitoring. J Neurooncol 2006, 78:91-97.
17. Zhu H., Acquaviva J., Ramachandran P., Boskovitz A., Woolfenden S., Pfannl R., et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A 2009, 106:2712-2716.
18. Fulci G., Dmitrieva N., Gianni D., Fontana E.J., Pan X., Lu Y., et al. The status of gene therapy for brain tumors. Expert Opin Biol Ther 2007, 7:197-208.
19. Jadus M.R., Irwin M.C., Irwin M.R., Horansky R.D., Sekhon S., Pepper K.A., et al. Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. Blood 1996, 87:5232-5241.
20. Prevezas C., Matard B., Pinquier L., Reygagne P. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 2009, 160:883-885.
21. Inada S., Tomidokoro T., Fukunari H., Sato T., Hatano T., Nishimura A., et al. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol 2009, 63:267-273.
22. Bundow D., Aboulafia D.M. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol 2004, 27:81-84.
23. Schwartz J.D., Howard W., Scadden D.T. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 1999, 13:283-284.
24. Ranganath S.H., Wang C.H. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials 2008, 29:2996-3003.
25. Montemor J.P., Peria F.M., Monti C.R., Petrilli L.S., Colli B.O., Carlotti C.G. Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment. Onkologie 2008, 31:435-439.
26. Chang S.M., Kuhn J.G., Robins H.I., Schold S.C., Spence A.M., Berger M.S., et al. A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 2001, 91:417-422.
27. Elkharraz K., Faisant N., Guse C., Siepmann F., Arica-Yegin B., Oger J.M., et al. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int J Pharm 2006, 314:127-136.
28. Rice A., Liu Y.B., Michaelis M.L., Himes R.H., Georg G.I., Audus K.L. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. J Med Chem 2005, 48:832-838.
29. Tange Y., Kondo A., Egorin M.J., Mania-Farnell B., Daneriallis G.M., Nakazaki H., et al. Interstitial continuous infusion therapy in a malignant glioma model in rats. Childs Nerv Syst 2009, 25:655-662.
30. Kioi M., Husain S.R., Croteau D., Kunwar S., Puri R.K. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 2006, 5:239-250.
31. Sheng Y., Liu C.S., Yuan Y., Tao X.Y., Yang F., Shan X.Q., et al. Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials 2009, 30:2340-2348.
32. Choi K.Y. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2010, 32:1880-1889.
33. Dou H.Y., Morehead J., Destache C.J., Kingsley J.D., Shlyakhtenko L., Zhou Y., et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 2007, 358:148-158.
34. Dou H., Destache C.J., Morehead J.R., Mosley R.L., Boska M.D., Kingsley J., et al. Development of a macrophage-based nanoparticle system for anti-retroviral drug delivery. Blood 2006, 108:2827-2835.